NEW YORK and SHANGHAI, May 1,
2020 /PRNewswire/ -- Cellular Biomedicine Group Inc.
(NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm
engaged in the drug development of immunotherapies for cancer and
stem cell therapies for degenerative diseases, today announced that
it will release its financial results for the first quarter ended
March 31, 2020 after the market
closes on Wednesday, May 6, 2020.
The Company will host a conference call and webcast with the
investment community on Wednesday, May
6th at 5:00 p.m. Eastern
Time, featuring remarks by Tony
Liu, CEO, CFO and Executive Director of CBMG.
|
What:
|
Cellular Biomedicine
Group First Quarter 2020 Results Conference Call
|
|
|
|
Date:
|
Wednesday, May 6,
2020
|
|
|
|
Time:
|
5:00 p.m. Eastern
Time
|
|
|
|
Live
Call:
|
Toll-Free:
+1-833-423-0438
International:
+1-918-922-6623
China: +86
800-870-0169 or +86 400-682-8609
Conference ID:
7690079
|
|
|
|
Webcast:
|
https://edge.media-server.com/mmc/p/wwg78hh5
|
|
|
|
Replay:
|
Toll-Free: (855)
859-2056
International: (404)
537-3406
Conference ID:
7690079
(Available
approximately two hours after the completion of the live call until
8:00 p.m. ET on May 20, 2020)
|
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops
proprietary cell therapies for the treatment of cancer and
degenerative diseases. It conducts immuno-oncology and stem cell
clinical trials in China using
products from its integrated GMP laboratory. The Company's GMP
facilities in China, consisting of
twelve independent cell production lines, are designed and managed
according to both China and U.S.
GMP standards. Its Shanghai
facility includes a "Joint Laboratory of Cell Therapy" with GE
Healthcare and a "Joint Cell Therapy Technology Innovation and
Application Center" with Thermo Fisher Scientific, which
partnerships focus on improving manufacturing processes for cell
therapies. CBMG currently has ongoing CAR-T Phase I clinical trials
in China. The China NMPA (formerly
CFDA) approved the Company's IND application for a Phase II trial
for AlloJoin®, CBMG's "Off-the-Shelf" allogenic haMPC therapy for
the treatment of Knee Osteoarthritis (KOA), and has accepted the
Company's IND application for a Phase II trial for ReJoin®
autologous haMPC therapy for the treatment of KOA. CBMG is included
in the broad-market Russell 3000® Index and the small-cap Russell
2000® Index, and the Loncar China BioPharma index. To learn more
about CBMG, please visit www.cellbiomedgroup.com.
Company Contact:
Derrick C.
Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-to-report-first-quarter-2020-results-on-may-6-2020-301051111.html
SOURCE Cellular Biomedicine Group